First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study - Wikidata - awgldk - TriplyDB

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

http://www.wikidata.org/entity/Q33378383

about

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (t First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.

P2860

Q33516118-FAFD94C2-BAF2-417F-9652-33E10102E045 Q35527102-9CED29D4-5D32-4D3B-BDB9-1E708C2C1BD8 Q53158825-6B6815A7-C2C1-479A-899C-53521A57DDCF

P2860

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

http://www.wikidata.org/entity/Q33378383

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

First line chemotherapy with p ...... : a multicenter phase II study

@ast

First line chemotherapy with p ...... : a multicenter phase II study

@en

type

label

First line chemotherapy with p ...... : a multicenter phase II study

@ast

First line chemotherapy with p ...... : a multicenter phase II study

@en

prefLabel

First line chemotherapy with p ...... : a multicenter phase II study

@ast

First line chemotherapy with p ...... : a multicenter phase II study

@en

P1433

Q33378383-F494189C-7077-4705-8E26-B0F5D5CEFFD3

P1476

Q33378383-6B400809-E1EC-40AC-99C0-589496329032

P2093

Q33378383-09F2FD6D-3603-4967-A60C-964065F911C9

Q33378383-450CD1D1-8548-4686-82EA-4771EA17A315

Q33378383-54377A31-BBC5-4BEB-A1B8-C62E7A00550D

Q33378383-6EDA4B59-0BA8-4361-B73C-2F468856FD82

Q33378383-98A0677B-8E4E-4DC1-80B3-C22398F7E73B

Q33378383-BCAE0280-ACF7-4312-B14B-BDAB93397DC4

Q33378383-D1357E70-A744-4291-B231-5FB10A0D9FA0

Q33378383-D6B67C6A-49FB-44AD-9639-A086C5649FCB

Q33378383-DE72F150-EEE5-4B6B-837C-FC0E6B04E380

Q33378383-F32E2527-3432-4257-8C7E-9A85B57D2F84

P2860

Q33378383-10277575-FF08-46C9-B59C-75FE529598C0

Q33378383-196F3FEC-DAEA-4BA4-A2D3-1F180508CC10

Q33378383-22E85B02-3503-4B82-B6BE-1C3AB72932E1

Q33378383-2DF924EE-27D1-4E35-9A41-DFECF1084A1A

Q33378383-302DC2D2-B621-469A-9FF9-3858EA309398

Q33378383-37E707DA-51E6-4714-AD33-5379D1C5E73B

Q33378383-3E5FCF3F-270B-403C-A4D4-9E07AF44C0D6

Q33378383-4F9596A0-D5EA-4E66-8CCF-05636CB16AF1

Q33378383-539F0A4A-9464-400C-B7BC-C8A47CA3073C

Q33378383-572581B4-7138-4598-A36F-F6E23D8C4640

P2888

Q33378383-C2B10F5F-3CF4-451A-A95F-9F758BD0C97E

P304

Q33378383-98BCC129-2896-4491-9968-84CD2753C585

P31

Q33378383-ABEC9DD7-9774-455B-A1FC-90904492F546

P356

Q33378383-DA65C871-38C0-4344-856B-2DC178BA3318

P407

Q33378383-4F774258-3025-4C8F-8415-AEA4578DF4E2

P433

Q33378383-DC6B3233-0F32-42DF-907B-ACDA1803D002

P478

Q33378383-CC98DE58-09EE-4A2B-B2FA-3151869EC624

P50

Q33378383-EB67BB98-B5CD-4D9D-BC08-738CA4F1F8FD

P577

Q33378383-4A91AFDE-9508-45FF-ABF9-D335E00ACD00

P5875

Q33378383-6F705E93-4780-4F4A-BDB6-5CC55651E131

P6179

Q33378383-FB7B33EF-2DEF-4119-874A-0E65C1FE9691

P698

Q33378383-FD891DF4-6DB4-4D78-95F2-B6D0FECFF0E6

P932

Q33378383-1E3A8953-2671-4547-A7DA-2ADCFB2FA0D2

P356

P1433

British Journal of Cancer

P1476

First line chemotherapy with p ...... : a multicenter phase II study

@en

P2093

A Antonuzzo

http://www.w3.org/2001/XMLSchema#string

A Fabbri

http://www.w3.org/2001/XMLSchema#string

C Tibaldi

http://www.w3.org/2001/XMLSchema#string

D Amoroso

http://www.w3.org/2001/XMLSchema#string

E Vasile

http://www.w3.org/2001/XMLSchema#string

F Innocenti

http://www.w3.org/2001/XMLSchema#string

G Tartarelli

http://www.w3.org/2001/XMLSchema#string

M Andreuccetti

http://www.w3.org/2001/XMLSchema#string

M Lo Dico

http://www.w3.org/2001/XMLSchema#string

R Di Marsico

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

P2888

P304

558-563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604187

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

Alfredo Falcone

P577

2008-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5638490

http://www.w3.org/2001/XMLSchema#string

P6179

1012950363

http://www.w3.org/2001/XMLSchema#string

P698

18212755

http://www.w3.org/2001/XMLSchema#string

P932

2243160

http://www.w3.org/2001/XMLSchema#string